



Dr. Stefanie Fischer

Medizinische Onkologie und Hämatologie · Dept. I

Contact

Dr. Stefanie Fischer
Switzerland

stefanie.fischer@kssg.ch

Homepage

www.kssg.ch/onkologie

Units

Medizinische Onkologie und Hämatologie

Publications (29)

Su E, Christinat Y, McKee T, Azzarello-Burri S, Jochum W, Fischer S, Rothermundt C. BRCA2 germline mutation carrier with five malignancies: a case report. *Hered Cancer Clin Pract* 2024; 22:27.

Wosny M, Aeppli S, Fischer S, Peres T, Rothermundt C, Hastings J. Factors Guiding Clinical Decision-Making in Genitourinary Oncology. *Cancer Med* 2024; 13:e70304.

Fischer S, Gillessen S, Stalder O, Terbuch A, Cathomas R, Schmid F, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Alex Kluth L, Seifert B, Templeton A, Mingrone W, Ufe M, Fischer N, Beyer J, Woelky R, Omlin A, Vogl U, Hoppe K, Kamradt J, Rothschild S, Rothermundt C. First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). *Eur Urol Open Sci* 2024; 68:68-74.

Akhoundova D, Fischer S, Triscott J, Lehner M, Thienger P, Maletti S, Jacquet M, Lubis D, Bubendorf L, Jochum W, Rubin M. Rare histologic transformation of a CTNNB1 (β -catenin) mutated prostate cancer with aggressive clinical course. *Diagn Pathol* 2024; 19:83.

Mc Laughlin A, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio-Poretti M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, Stathis A, Halbherr S, Huisinga W, Jörgler M, Kloft C. Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. *Cancer Chemother Pharmacol* 2024; 94:349-360.

Peres T, Aeppli S, Fischer S, Gysel K, Rothermundt C. Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer. *J Cancer Res Clin Oncol* 2024; 150:84.

Boormans J, Sylvester R, Anson-Cartwright L, Glicksman R, Hamilton R, Hahn E, Daugaard G, Lauritsen J, Wagner T, Avuzzi B, Nicolai N, del Muro X, Aparicio J, Stalder O, Rothermundt C, Fischer S, Laguna M. Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office. *Eur Urol Oncol* 2023

Kelly W, Danila D, Lin C, Lee J, Matsubara N, Ward P, Armstrong A, Pook D, Kim M, Dorff T, Fischer S, Lin Y, Horvath L, Sumey C, Yang Z, Jurida G, Smith K, Connarn J, Penny H, Stieglmaier J, Appleman L. Xaluritamid, a STEAP1 \times CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. *Cancer Discov* 2023:OF1-OF14.

Templeton A, Omlin A, Berthold D, Beyer J, Burger I, Eberli D, Engeler D, Fankhauser C, Fischer S, Gillessen S, Nicolas G, Kroeze S, Lorch A, Müntener M, Papachristofilou A, Schäfer N, Seiler D, Stenner-Liewen F, Tsantoulis P, Vlajnic T, Zilli T, Zwahlen D, Cathomas R. Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer. *Swiss Med Wkly* 2023; 153:40108.

Silzle T, Kahlert C, Albrich W, Nigg S, Demmer-Steingruber R, Driessen C, Fischer S. Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study. *Swiss Med Wkly* 2023; 153:40090.

Patrikidou A, Cazzaniga W, Berney D, Boormans J, de Angst I, Di Nardo D, Fankhauser C, Fischer S, Gravina C, Gremmels H, Heidenreich A, Janisch F, Leão R, Nicolai N, Oing C, Oldenburg J, Shepherd R, Tandstad T, Nicol D. European Association of Urology Guidelines on Testicular Cancer: 2023 Update. *Eur Urol* 2023; 84:289-301.

Menges D, Piatti M, Omlin A, Cathomas R, Benamran D, Fischer S, Iselin C, Kueng M, Lorch A, Prause L, Rothermundt C, O'Meara Stern A, Zihler D, Lippuner M, Braun J, Cerny T, Puhan M. Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment. *Eur Urol Open Sci* 2023; 51:26-38.

Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Seifert B, Alex Kluth L, Ufe M, Mingrone W, Templeton A, Fischer N, Rothschild S, Woelky R, Gillessen S, Cathomas R. The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. *Eur Urol Open Sci* 2023; 50:57-60.

Neuenschwander A, Lonati C, Antonelli L, Papachristofilou A, Cathomas R, Rothermundt C, Templeton A, Gulamhusein A, Fischer S, Gillessen S, Hermanns T, Lorch A, Mattei A, Fankhauser C. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. *Eur Urol Focus* 2022

Fischer S, Götze T, Omlin A, Baird R, Dawson K, Zitt C, Arany Z, Tresch G, Fiedler U, Jeger S, Fung S, Legenne P, Leupin N, Schneeweiss A, Fremd C. A Case of Sustained Tumor Regression With MPO274, a Novel DARPIn Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab. *JCO Precis Oncol* 2022; 6:e2200006.

Aeppli S, Engeler D, Fischer S, Omlin A, Pratsinis M, Hermann C, Rothermundt C. Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018. *Swiss Med Wkly* 2022; 152:w30175.

Terbuch A, Posch F, Bauernhofer T, Jost P, Partl R, Stranzl-Lawatsch H, Baciarello G, Fizazi K, Giannatempo P, Verzoni E, Sweeney C, Ravi P, Tran B, Basso U, White J, Vincenzi B, Oing C, Cutuli H, Dieckmann K, Gamulin M, Chovanec M, Fankhauser C, Heidenreich A, Mohamad O, Thibault C, Fischer S, Gillessen S. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. *Int J Radiat Oncol Biol Phys* 2022; 113:825-832.

Seidel C, Hentrich M, Zschäbitz S, Paffenholz P, Heidenreich A, Nestler T, Tran B, Fischer S, Daugaard G, Ochsenreither S, Brito M, Zengerling F, Schwab C, Bokemeyer C, Oing C. Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). *World J Urol* 2022; 40:355-361.

Achard V, Putora P, Omlin A, Zilli T, Fischer S. Metastatic Prostate Cancer: Treatment Options. *Oncology* 2021; 100:48-59.

Beyer J, Stenner F, Spahn M, Seiler R, Rothermundt C, Roth B, Papachristofilou A, Omlin A, Lorch A, Honecker F, Hermanns T, Gross T, Gillessen S, Fischer S, Fankhauser C, Cathomas R, Bode P, Berthold D, Bühner E. Swiss germ-cell cancer consensus recommendations. *Swiss Med Wkly* 2021; 151

Fankhauser C, Tandstad T, Nicolai N, Nicol D, Leão R, Muilwijk T, Janisch F, Mayor de Castro J, Gremmels H, Fizazi K, Fischer S, Boormans J, Bokemeyer C, Algaba F, Albers P, Oldenburg J, Pilar Laguna M. Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. *Eur Urol* 2021; 80:4-6.

Baird R, Fischer S, Azaro A, Harstrick A, Stumpp M, Leupin N, Dawson K, Fiedler U, Zitt C, Rodón J, Harris A, Lord S, Middleton M, Linossi C, Omlin A. First-in-Human Phase I Study of MPO250, a First-in-Class DARPIn Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. *J Clin Oncol* 2020; 39:145-154.

Fischer S, Clements S, McWilliam A, Green A, Descamps T, Oing C, Gillessen Sommer S. Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer. *Cancer Treat Res Commun* 2020; 25:100256.

Aeppli S, Sternberg C, Schmidinger M, Rini B, Porta C, Omlin A, Oldenburg J, McDermott D, Gruenwald V, Larkin J, Fischer S, Escudier B, Eisen T, Eboulet E, Rothermundt C. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. *ESMO Open* 2020; 5

Fischer S, Langberg C, Ståhl O, Fankhauser C, Hamid A, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen Sommer S, Wheeler M, Hentrich M, Heidenreich A, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Global Germ-Cell Cancer Group. Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. *J Clin Oncol* 2019;JCO1901876.

Fischer S, Ali O, Jochum W, Kluckert J, Flatz L, Siano M. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. *Oncol Res Treat* 2018; 41:391-394.

Fischer S, Cohn-Cedermark G, Ståhl O, Chau C, Arriola E, Marti K, Hutton P, Laguerre B, Maroto P, Beyer J, Dieckmann K, Lorch A, Tandstad T, Wheeler M, Porfiri E, Flechon A, Aparicio J, Klingbiel D, Skrbinc B, Basso U, Shamash J, Gillessen Sommer S. Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. *J Clin Oncol* 2016; 35:194-200.

Fischer S, Gillessen Sommer S, Rothermundt C. Sequence of treatment in locally advanced and metastatic renal cell carcinoma. *Transl Androl Urol* 2015; 4:310-25.

Fischer S, Weber J, Senn-Schönenberger I, Cerny T, Hundsberger T. Neuroborreliosis Mimicking Leptomeningeal Carcinomatosis in a Patient With Breast Cancer: A Case Report. *J Investig Med High Impact Case Rep* 2014; 2:2324709614529417.

Projects (14)

Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial.

Clinical Studies - Oct 31, 2024 - Dec 31, 2028

Ongoing

A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents

Clinical Studies - Oct 18, 2023 - Dec 31, 2028

Ongoing

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Clinical Studies - Feb 7, 2023 - Dec 31, 2026

Ongoing

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-resistant Prostate Cancer

Clinical Studies - Nov 30, 2022 - Dec 31, 2026

Ongoing

Covid 19 Impfantwort, Bedarf und Reaktion auf mögliche Booster- Impfung bei Patienten mit soliden Neoplasien

Clinical Studies - Oct 1, 2021 - Feb 28, 2021

Automatically Closed

SAKK 67/20 Open-label single-stage phase 1B study of the new micellar docetaxel compound Docecal in patients with advanced castra-tion-resistant prostate cancer

Clinical Studies - May 28, 2021 - Dec 31, 2024

Completed

Response to COVID-19 vaccination and COVID-19 infections after vaccination in patients with haematological malignancies

Clinical Studies - May 1, 2021 - Oct 1, 2022

Completed

MK-7902-005 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

Clinical Studies - Mar 17, 2021 - May 7, 2030

Ongoing

A Phase II, Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Neoadjuvant And Adjuvant Tiragolumab Plus Atezolizumab, With Or Without Platinum-Based Chemotherapy, In Patients With Previously Untreated Locally Advanced Resectable Stage II, Ila, Or Select IIIb Non-Small Cell Lung Cancer

Clinical Studies - Feb 12, 2021 - Jul 24, 2024

Aborted

A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS

Clinical Studies - Jul 17, 2020 - Jul 17, 2022

Automatically Closed

SAKK 01/18 Reduced intensity radio-chemotherapy for satge IIA/B seminoma. A multicenter, open label phase II trial with 2 cohorts

Clinical Studies - Jul 24, 2019 - Jul 24, 2030

Ongoing

Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial

Clinical Studies - Oct 15, 2015 - Dec 31, 2029

Ongoing

An open-label, multicohort, phase II study of MPDL3280A in advanced solid tumors

Clinical Studies - Jul 8, 2015 - Jul 31, 2019

Automatically Closed

Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)

Clinical Studies - Jul 7, 2014 - Dec 31, 2026

Ongoing